{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:50:13Z","timestamp":1773071413950,"version":"3.50.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cefepime and piperacillin-tazobactam are commonly used broad-spectrum antibiotics used to treat patients with potential gram-negative bacterial sepsis. Piperacillin-tazobactam has been shown to be associated with acute kidney injury (AKI). However, it has not been compared with cefepime in patients with septic shock. We compared the effects of cefepime and piperacillin-tazobactam on the incidence of severe AKI in patients with septic shock.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective, multicenter, inverse probability-of-treatment weighted cohort study conducted in 220 geographically diverse community and teaching hospitals across the United States. Adult patients were included if they had septic shock on hospital admission and received cefepime or piperacillin-tazobactam. The proportions of patients in whom stage 3 AKI occurred during hospitalization were compared between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 8427 patients included in the final cohort, 4569 received cefepime and 3858 received piperacillin-tazobactam. Patients had a mean (SD) age of 66.2 (15.2) years, and 45.3% were female; the mean (SD) estimated glomerular filtration rate was 48 (24) mL\/min\/1.73 m2 on the day of admission. In the weighted cohort, stage 3 AKI occurred in 9.9% receiving cefepime and 9.8% receiving piperacillin-tazobactam (odds ratio, 0.98 [95% confidence interval, .84\u20131.15]; P = .82). In terms of secondary outcomes, there was no significant difference between cefepime and piperacillin-tazobactam with regard to renal replacement therapy, in-hospital death, major adverse kidney events, stage 1 AKI, stage 2 AKI, maximum recorded serum creatinine, or hospital length of stay<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Among hospitalized patients with septic shock, there was no difference between cefepime and piperacillin-tazobactam in the occurrence of severe AKI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae600","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T04:26:06Z","timestamp":1733286366000},"page":"770-776","source":"Crossref","is-referenced-by-count":3,"title":["A National Retrospective Cohort Study Comparing the Effects of Cefepime Versus Piperacillin-Tazobactam on the Development of Severe Acute Kidney Injury in Patients With Septic Shock"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-4703","authenticated-orcid":false,"given":"Asad E","family":"Patanwala","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health, School of Pharmacy, The University of Sydney , Sydney, New South Wales ,","place":["Australia"]},{"name":"Department of Pharmacy, Royal Prince Alfred Hospital , Camperdown, New South Wales ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9440-465X","authenticated-orcid":false,"given":"David E","family":"Nix","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona , Tucson, Arizona ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0322-5822","authenticated-orcid":false,"given":"Thomas E","family":"Hills","sequence":"additional","affiliation":[{"name":"Medical Research Institute of New Zealand , Wellington ,","place":["New Zealand"]},{"name":"Department of Infectious Diseases, Auckland City Hospital , Auckland ,","place":["New Zealand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-9921","authenticated-orcid":false,"given":"Brian L","family":"Erstad","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona , Tucson, Arizona ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"2025043020385246800_ciae600-B1","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"key":"2025043020385246800_ciae600-B2","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2023.20583","article-title":"Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: the ACORN randomized clinical trial","volume":"330","author":"Qian","year":"2023","journal-title":"JAMA"},{"key":"2025043020385246800_ciae600-B3","doi-asserted-by":"crossref","first-page":"e02658-18","DOI":"10.1128\/AAC.02658-18","article-title":"Incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam, cefepime, or meropenem","volume":"63","author":"Blevins","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025043020385246800_ciae600-B4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijantimicag.2017.02.023","article-title":"Acute kidney injury risk associated with piperacillin\/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function","volume":"50","author":"Jeon","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2025043020385246800_ciae600-B5","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/cid\/ciy724","article-title":"Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal \u03b2-lactams with vancomycin","volume":"68","author":"Schreier","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025043020385246800_ciae600-B6","author":"PINC AI Applied Sciences, Premier Inc"},{"key":"2025043020385246800_ciae600-B7","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2025043020385246800_ciae600-B8","first-page":"19","article-title":"Section 2: AKI definition. KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kellum","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2025043020385246800_ciae600-B9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000363725","article-title":"Clinical trial endpoints in acute kidney injury","volume":"127","author":"Billings","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"2025043020385246800_ciae600-B10","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2025043020385246800_ciae600-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v009.i08","article-title":"Analysis of complex survey samples","volume":"9","author":"Lumley","year":"2004","journal-title":"J Stat Softw"},{"key":"2025043020385246800_ciae600-B12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.32614\/RJ-2021-073","article-title":"MatchThem: matching and weighting after multiple imputation","volume":"13","author":"Pishgar","year":"2021","journal-title":"R J"},{"key":"2025043020385246800_ciae600-B13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamainternmed.2024.0581","article-title":"Mortality of patients with sepsis administered piperacillin-tazobactam vs cefepime","volume":"184","author":"Chanderraj","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2025043020385246800_ciae600-B14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1089\/sur.2022.128","article-title":"Kidney injury in critically ill patients treated with vancomycin and Zosyn or an alternative: a systematic review and meta-analysis","volume":"23","author":"Blears","year":"2022","journal-title":"Surg Infect (Larchmt)"},{"key":"2025043020385246800_ciae600-B15","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/phar.1851","article-title":"Is the combination of piperacillin-tazobactam and vancomycin associated with development of acute kidney injury? A meta-analysis","volume":"36","author":"Giuliano","year":"2016","journal-title":"Pharmacotherapy"},{"key":"2025043020385246800_ciae600-B16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/medicina59040691","article-title":"Evaluating the nephrotoxicity of area-under-the-curve-based dosing of vancomycin with concomitant antipseudomonal beta-lactam antibiotics: a systematic review and meta-analysis","volume":"59","author":"Chiu","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"2025043020385246800_ciae600-B17","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","article-title":"The prevention and treatment of missing data in clinical trials","volume":"367","author":"Little","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae600\/60963875\/ciae600.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/4\/770\/60963875\/ciae600.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/4\/770\/60963875\/ciae600.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:39:02Z","timestamp":1746059942000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/4\/770\/7917497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,5]]},"published-print":{"date-parts":[[2025,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae600","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4,15]]},"published":{"date-parts":[[2024,12,5]]}}}